Cambrex Opens Large Scale API Manufacturing Facility and Invests in Supporting Waste Water Treatment Plant at Its Karlskoga, ...
September 26 2017 - 7:30AM
Cambrex Corporation (NYSE:CBM), the leading manufacturer of small
molecule innovator and generic Active Pharmaceutical Ingredients
(APIs), today announced that it has completed the installation of
new, large scale manufacturing capacity at its cGMP facility in
Karlskoga, Sweden and has also undertaken a multi-year construction
project to increase the site’s waste water processing capabilities.
The expansion of the site’s manufacturing
capabilities included the installation of various multi-purpose
reactors, ranging from 4m3 to 12m3 in size, in addition to a 9m³
hydrogenation reactor.
The construction of a new waste water treatment
plant to support the expansion and improve existing biological
processes, is being phased over a three-year period. The 30.5M SEK
($3.5M) investment will process over 4,000m3 of water each day and
handle variations in the composition of effluent. The majority of
the construction project will be completed in 2017, with additional
upgrades in 2018 and 2019. When completed, the facility will reduce
the emission of nitrogen, total organic compounds and suspended
material, improving the site’s environmental footprint.
“Our Karlskoga site is a crucial part of the
company’s global manufacturing network, and these investments, to
not only to increase capacity, but also to the supporting
infrastructure, will enable the site to work efficiently both now,
and into the future,” commented Bjarne Sandberg, Managing Director,
Cambrex Karlskoga. He added, “At Cambrex we are committed to
investing in small molecule development and manufacturing
capabilities, and ensuring our facilities are both flexible and
efficient to respond to the evolving needs of our customers.”
The expansion at Cambrex’s Swedish site is part
of an ongoing strategic campaign to increase manufacturing capacity
across its global network, and follows the announcement of the
construction of a $24M, 4,500ft² highly potent API manufacturing
facility at the Charles City, Iowa site, which is due to open in
2019.
About CambrexCambrex
Corporation is an innovative life sciences company that provides
products, services and technologies to accelerate the development
and commercialization of small molecule therapeutics. The
Company offers Active Pharmaceutical Ingredients (APIs), advanced
intermediates and enhanced drug delivery products for branded and
generic pharmaceuticals. Development and manufacturing capabilities
include enzymatic biotransformations, high potency APIs, high
energy chemical synthesis and controlled substances. For more
information, please visit www.cambrex.com
Contact:
Alex
Maw
Director, Marketing and
Communications
Tel: +44 7803 443
155
Email: alex.maw@cambrex.com
Cambrex (NYSE:CBM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cambrex (NYSE:CBM)
Historical Stock Chart
From Apr 2023 to Apr 2024